|
Academic/Biomedical Research
News & Jobs
|
|
|
|
|
|
|
|
|
|
|
|
|
Free Newsletters
Archive
My Subscriptions
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers
Regional News
US & Canada
Biotech Bay
Biotech Beach
Genetown
Pharm Country
BioCapital
BioMidwest
Bio NC
BioForest
Southern Pharm
BioCanada East
US Device
Europe
Asia
Company Profiles
Research Store
Research Events
Post an Event
Real Estate
Business Opportunities
|
|
|
|
|
News | News By Subject | News by Disease |
News By Date | Search News
|
|
|
Nobel Prize-Winner's Stem Cells Help GlaxoSmithKline (GSK) Pinpoint Risks
10/22/2012 8:11:55 AM
GlaxoSmithKline Plc (GSK) is applying Shinya Yamanaka’s Nobel Prize-winning discovery in stem cells to identify heart risks linked to experimental drugs earlier in the development process. Yamanaka was awarded the Nobel Prize in medicine this month for his work in turning ordinary skin cells into induced pluripotent stem, or iPS, cells with the potential to become any cell in the body. That breakthrough has enabled the London-based drugmaker to create heart-muscle stem cells that may be used to test compounds for cardiovascular safety, said Jason Gardner, head of Glaxo’s early-stage regenerative medicine research. About half of all experimental drugs fail for safety reasons, and half of those failures are due to toxic effects on the heart, Gardner said. Finding that risk even before animal testing could potentially save drugmakers millions of dollars in clinical-trial costs and better protect patients, he said. “I call this a low-risk, must-do approach to stem cells,” Gardner said in an interview in Upper Providence, Pennsylvania, where Glaxo has been building on research using iPS cells that began in the U.K. in 2010. “It’s on the verge of being used now for decision-making.”
|
|
|
|
|
|
|
|
|
|
|